Chong, Li Ming http://orcid.org/0000-0002-3742-2704
Wang, Peter http://orcid.org/0000-0002-4925-1738
Lee, V. Vien
Vijayakumar, Smrithi
Tan, Hong Qi
Wang, Fu Qiang
Yeoh, Teri Danielle You Ying
Truong, Anh T. L.
Tan, Lester Wen Jeit http://orcid.org/0000-0003-0323-4964
Tan, Shi Bei
Senthil Kumar, Kirthika
Hau, Eric
Vellayappan, Balamurugan A.
Blasiak, Agata
Ho, Dean http://orcid.org/0000-0002-7337-296X
Funding for this research was provided by:
National Research Foundation Singapore (AISG-GC-2019-002)
Ministry of Health -Singapore (MOH-OFLCG18May-0028)
Article History
Received: 30 November 2023
Revised: 29 February 2024
Accepted: 4 March 2024
First Online: 21 March 2024
Competing interests
: DH, AB, KSK, SBT, ATLT and LWJT are co-inventors of previously filed pending patents on artificial intelligence-based therapy development. DH is a shareholder of KYAN Therapeutics, which has licensed intellectual property pertaining to AI-based oncology drug development. The findings from this study are being made available for public benefit, and no intellectual property rights arising from the work reported here are being pursued. The remaining authors declare no competing interests.